Cancer diagnoses in Europe are expected to increase 19% by 2040, and cancer deaths are expected to increase by 27%.1
Meanwhile, innovative treatments are emerging at an unprecedented pace. As populations age, healthcare inequities widen, and adverse environmental factors become more prevalent, will these breakthroughs reach patients in a fair and timely way to transform outcomes and improve the lives of millions of people?
The 2024 European Society of Medical Oncology (ESMO) Congress featured the latest advances in oncology, reflecting on critical areas of drug development, technology, and patient-centered care. There were several critical themes, questions, and data shared across over 200 sessions and 2,000 abstracts that are highly relevant to patient communities and their advocates.
This report aims to highlight these themes and suggest ways in which the data and ideas shared at ESMO, and the incredible advances in oncology, should be considered through the lens of the ultimate beneficiary – oncology patients and their families.
1. European Commission. (2024, August). Impact of population ageing on the burden of cancer up to 2040 in EU/EFTA1 countries. European Cancer Information System. https://ecis.jrc.ec.europa.eu/sites/default/files/2024-09/2024_08_Factsheet_2040CancerEstimates.pdf
Download our patient-focused report
"*" indicates required fields
